TN2011000203A1 - 1-(arylsulfonyl) -4- (piperazine -1- yl) 1h - benzimidazoles servant de ligands de la s -hydroxytryptamine -6 - Google Patents

1-(arylsulfonyl) -4- (piperazine -1- yl) 1h - benzimidazoles servant de ligands de la s -hydroxytryptamine -6

Info

Publication number
TN2011000203A1
TN2011000203A1 TN2011000203A TN2011000203A TN2011000203A1 TN 2011000203 A1 TN2011000203 A1 TN 2011000203A1 TN 2011000203 A TN2011000203 A TN 2011000203A TN 2011000203 A TN2011000203 A TN 2011000203A TN 2011000203 A1 TN2011000203 A1 TN 2011000203A1
Authority
TN
Tunisia
Prior art keywords
benzimidazoles
arylsulfonyl
piperazine
hydroxytryptamine
ligands
Prior art date
Application number
TN2011000203A
Other languages
English (en)
French (fr)
Inventor
Patrick M Andrae
Heedong Yun
Albert J Robichaud
Simon N Haydar
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41404503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000203(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of TN2011000203A1 publication Critical patent/TN2011000203A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/22—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TN2011000203A 2008-11-11 2011-04-22 1-(arylsulfonyl) -4- (piperazine -1- yl) 1h - benzimidazoles servant de ligands de la s -hydroxytryptamine -6 TN2011000203A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11329608P 2008-11-11 2008-11-11
PCT/US2009/063816 WO2010056644A1 (en) 2008-11-11 2009-11-10 1- (ARYLSULFONYL) -4- (PI PERAZIN-I -YL) -IH-BENZ IMIDAZOLES AS δ-HYDROXYTRYPTAMINE- 6 LIGANDS

Publications (1)

Publication Number Publication Date
TN2011000203A1 true TN2011000203A1 (fr) 2012-12-17

Family

ID=41404503

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000203A TN2011000203A1 (fr) 2008-11-11 2011-04-22 1-(arylsulfonyl) -4- (piperazine -1- yl) 1h - benzimidazoles servant de ligands de la s -hydroxytryptamine -6

Country Status (41)

Country Link
US (1) US8063053B2 (enExample)
EP (1) EP2285784B1 (enExample)
JP (1) JP5087171B2 (enExample)
KR (1) KR101323417B1 (enExample)
CN (1) CN102209713B (enExample)
AP (1) AP2814A (enExample)
AR (1) AR074325A1 (enExample)
AU (1) AU2009314221B2 (enExample)
BR (1) BRPI0920682A2 (enExample)
CA (1) CA2740262C (enExample)
CL (1) CL2011001050A1 (enExample)
CO (1) CO6440548A2 (enExample)
CR (1) CR20110247A (enExample)
CU (1) CU24020B1 (enExample)
CY (1) CY1113025T1 (enExample)
DK (1) DK2285784T3 (enExample)
DO (1) DOP2011000130A (enExample)
EA (1) EA018369B1 (enExample)
EC (1) ECSP11011045A (enExample)
ES (1) ES2389694T3 (enExample)
GE (1) GEP20135805B (enExample)
HR (1) HRP20120561T1 (enExample)
IL (1) IL212213A0 (enExample)
MA (1) MA32788B1 (enExample)
ME (1) ME01129B (enExample)
MX (1) MX2011004996A (enExample)
MY (1) MY156324A (enExample)
NI (1) NI201100093A (enExample)
NZ (1) NZ592563A (enExample)
PE (1) PE20120026A1 (enExample)
PL (1) PL2285784T3 (enExample)
PT (1) PT2285784E (enExample)
RS (1) RS52381B (enExample)
SA (1) SA109300673B1 (enExample)
SI (1) SI2285784T1 (enExample)
SV (1) SV2011003902A (enExample)
TN (1) TN2011000203A1 (enExample)
TW (1) TWI481605B (enExample)
UA (1) UA100192C2 (enExample)
WO (1) WO2010056644A1 (enExample)
ZA (1) ZA201103283B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2580857A1 (en) * 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2580844A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
JP5080256B2 (ja) * 2004-09-20 2012-11-21 ゼノン・ファーマシューティカルズ・インコーポレイテッド 二環式複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼ（ＳＣＤ）のインヒビターとしてのそれらの使用
TW200624427A (en) * 2004-09-20 2006-07-16 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CN104557726B (zh) * 2013-10-19 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
WO2016004882A1 (en) 2014-07-08 2016-01-14 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
WO2017052394A1 (en) 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
EP3530651A1 (en) 2018-02-21 2019-08-28 Adamed sp. z o.o. Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists
US12398097B2 (en) 2019-07-29 2025-08-26 Vanderbilt University WDR5-MYC inhibitors
IL297448A (en) * 2020-04-22 2022-12-01 Recurium Ip Holdings Llc Preparation of an selective estrogen receptor degrader

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3155008B2 (ja) * 1994-07-26 2001-04-09 ファイザー・インコーポレーテッド セロトニンアゴニストおよびアンタゴニストとしての４−インドール誘導体
US5849759A (en) * 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
WO1999002502A2 (en) 1997-07-11 1999-01-21 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
GB9716656D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
SI0930302T1 (en) * 1998-01-16 2003-10-31 F. Hoffmann-La Roche Ag Benzosulfone derivatives
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
WO2000009498A1 (en) * 1998-08-10 2000-02-24 Partnership Of Michael E. Garst, George Sachs And Jai Moo Shin Prodrugs of proton pump inhibitors
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
NZ524675A (en) 2000-10-20 2004-09-24 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-N1-(benzensulfonyl) indoles and their use in therapy
SE0003810D0 (sv) * 2000-10-20 2000-10-20 Pharmacia Ab Novel compounds their use and preparations
HUP0303756A3 (en) * 2000-11-02 2009-08-28 Wyeth Corp 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands and process for their preparation and pharmaceutical compositions containing them
US7034029B2 (en) * 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
EP1401812B1 (en) * 2001-06-15 2006-06-28 F. Hoffmann-La Roche Ag 4-piperazinylindole derivatives with 5-ht6 receptor affinity
WO2003026666A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
AU2003284142A1 (en) 2002-10-15 2004-05-04 Synta Pharmaceuticals Corp Aromatic bicyclic heterocyles to modulate 1L-12 production
WO2005112938A2 (en) 2004-04-13 2005-12-01 Synta Pharmaceuticals Corp. Disalt inhibitors of il-12 production
WO2006015259A2 (en) 2004-07-28 2006-02-09 Irm Llc Compounds and compositions as modulators of steroid hormone nuclear receptors
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders

Also Published As

Publication number Publication date
CR20110247A (es) 2011-06-24
HRP20120561T1 (hr) 2012-07-31
AU2009314221A1 (en) 2010-05-20
MY156324A (en) 2016-02-15
NZ592563A (en) 2012-10-26
KR101323417B1 (ko) 2013-10-29
UA100192C2 (en) 2012-11-26
ZA201103283B (en) 2012-01-25
NI201100093A (es) 2011-10-31
IL212213A0 (en) 2011-06-30
DK2285784T3 (da) 2012-07-23
CN102209713B (zh) 2014-07-02
AP2011005664A0 (en) 2011-04-30
CU20110101A7 (es) 2012-01-31
HK1158647A1 (en) 2012-07-20
CY1113025T1 (el) 2016-04-13
CA2740262C (en) 2013-05-28
PE20120026A1 (es) 2012-02-12
MX2011004996A (es) 2011-05-25
CN102209713A (zh) 2011-10-05
PT2285784E (pt) 2012-09-19
JP5087171B2 (ja) 2012-11-28
AU2009314221B2 (en) 2012-08-30
JP2012508275A (ja) 2012-04-05
TW201022247A (en) 2010-06-16
AP2814A (en) 2013-12-31
EA018369B1 (ru) 2013-07-30
CU24020B1 (es) 2014-07-30
DOP2011000130A (es) 2017-04-30
CO6440548A2 (es) 2012-05-15
ECSP11011045A (es) 2011-06-30
US20100120779A1 (en) 2010-05-13
EP2285784A1 (en) 2011-02-23
SV2011003902A (es) 2011-07-05
ES2389694T3 (es) 2012-10-30
PL2285784T3 (pl) 2012-12-31
KR20110075013A (ko) 2011-07-05
BRPI0920682A2 (pt) 2016-09-27
ME01129B (me) 2013-03-20
MA32788B1 (fr) 2011-11-01
SA109300673B1 (ar) 2013-05-25
WO2010056644A8 (en) 2010-11-18
AR074325A1 (es) 2011-01-05
RS52381B (sr) 2012-12-31
EA201100696A1 (ru) 2011-10-31
GEP20135805B (en) 2013-04-10
SI2285784T1 (sl) 2012-08-31
CL2011001050A1 (es) 2011-08-19
EP2285784B1 (en) 2012-07-04
TWI481605B (zh) 2015-04-21
WO2010056644A1 (en) 2010-05-20
CA2740262A1 (en) 2010-05-20
US8063053B2 (en) 2011-11-22

Similar Documents

Publication Publication Date Title
TN2011000203A1 (fr) 1-(arylsulfonyl) -4- (piperazine -1- yl) 1h - benzimidazoles servant de ligands de la s -hydroxytryptamine -6
MA29549B1 (fr) Arylpyrazoles substitues destines a etre utilises contre des parasites
MA29800B1 (fr) Formes polymorphes de sel benzoate de 2-[[ 6-[(3r)-3-amino-1-piperidinyl ]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-benzonitrile, et leurs procedes d'utilisation
MA30405B1 (fr) Derives de 4-benzylphtalazinone substitues en 2 en tant qu'antagonistes des histamines hl et h3
JO3643B1 (ar) مركبات صيدلانية جديدة
MA32134B1 (fr) Composés hétérocycliques
GT200600134A (es) Compuestos novedosos de derivados de aminosulfonilo
TW200738666A (en) Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
MA31683B1 (fr) Composes et procedes pour moduler fxr
MX2007008555A (es) Amino-imidazolonas para la inhibicion de (-secretasa.
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
MA31580B1 (fr) Derives de bicyclolactames substitués
MXPA04003007A (es) Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades.
NO20071521L (no) Nye fenylaminopyrimidin derivater som hemmere av BCR-ABL kinase
MA30531B1 (fr) Anticorps anti-dll4 et leurs procedes d'utilisation
WO2008097538A8 (en) Therapeutic agents
NO20070526L (no) Kinazolindionderivater som parp-inhibitorer
MA31903B1 (fr) Derives de thiazole utilises comme inhibiteur de la pi 3 kinase
ATE469888T1 (de) Indazol-, benzisoxazol- und benzisothiazol- kinaseinhibitoren
NO20082481L (no) Nye 2-aminoheterosykluser som er nyttige ved behandling av ABETA-relaterte patologier
MA30166B1 (fr) Imidazoles substitues et leur utilisation comme pesticides.
SI2091948T1 (sl) Novi inhibitorji glutaminil ciklaze
GEP20115211B (en) Terphenyl derivatives for treatment of alzheimer' s disease
MA30351B1 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.